Synthetic approaches to a mononucleotide prodrug of cytarabine

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 10-12, 2005, Pages 1635-1649

  Bazzanini, R ^a,c   Gouy, M H ^a   Peyrottes, S ^a   Gosselin, G ^a   Perigaud C ^a   Manfredini, S ^b  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b UNIVERSITY OF FERRARA   (Italy)

^c EUROPEAN PATENT OFFICE   (Netherlands)

Author keywords

Ara C; Leukemia; Phosphotriester; Prodrug

Indexed keywords

1 BETA DEXTRO ARABINOFURANOSYL CYTOSINE 5' BIS(S PIVALOYL 2 THIOETHYL)PHOSPHATE; CYTARABINE; ETHER DERIVATIVE; FLUORIDE; NUCLEOSIDE; PHOSPHATE; PHOSPHORAMIDOUS ACID; PRODRUG; TETRABUTYLAMMONIUM; UNCLASSIFIED DRUG;

ARTICLE; DRUG SYNTHESIS; MIGRATION; MOLECULAR INTERACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DEOXYRIBONUCLEOTIDES; PRODRUGS;

ARA;

EID: 29244452640     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770500267006     Document Type: Article

References (46)

1. Carey, R.W.; Ribas-Mimdo, M.; Ellison, R.R. Comparative study of cytosine arabinoside therapy alone and in combination with thioguanine, mercaptopurine, or daunorubicine in acute myelocytic leukemia. Cancer Commun. 1975, 36, 1560-1566.
2. Tallman, M.S. Therapy of acute myeloid leukemia. Cancer Control 2001, 8, 62-78.
3. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002, 3, 415-424.
4. Liliemark, J.O.; Plunkett, W.; Dixon, D.O. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1985, 45, 5952-5957.
5. Plunkett, W.; Liliemark, J.O.; Estey, E.; Keating, M.J. Saturation of AraCTP accumulation during high-dose araC therapy: Pharmacologic rationale for intermediate-dose araC. Semin. Oncol. 1987, 14, 159-166.
6. Kufe, D.W.; Major, P.P.; Egan, E.M.; Beardsley, G.P. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem. 1980, 255, 8997-8900.
7. Major, P.P.; Egan, E.M.; Herrick, D.J.; Kufe, D.W. Effect of ara-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem. Pharmacol. 1982, 31, 2937-2940.
8. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15, 875-890.
9. Owens, J.K.; Shewach, D.S.; Ullman, B.; Mitchell, B.S. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycyttidine kinase gene. Cancer Res. 1992, 52, 2389-2393.
10. Dumontet, C.; Fabianowska-Majewska, K.; Mantincic, D.; Bauchu-Callet, E.; Tigaud, I.; et al. Common resistance mechanisms to deoxynucleoside analogues in variants of human erythroleukaemic line K562. Brit. J. Haematol. 1999, 106, 78-85.
11. Veuger, M.J.T.; Honders, M.W.; Willemze, R.; Barge, R.M.Y. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. Eur. J. Haematol. 2002, 69, 171-178.
12. Galmarini, C.M.; Thomas, X.; Graham, K.; Jafaari, A.; Cros, E.; et al. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukemia patients treated with cytarabine. Brit. J. Haematol. 2003, 122, 53-60.
13. Hamada, A.; Kawaguchi, T.; Nakano, M. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. 2002, 41, 705-718.
14. Hadfield, A.F.; Sartorelli, A.C. The pharmacology of prodrugs of 5-fluorouracil and 1-beta-D-arabinofuranosylcytosine. Adv. Pharmacol. Chem. 1984, 20, 21-67.
15. Colin, B.; Jones, N.M.; McGuigan, C.; Riley, P.A. Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug AraC. Nucl. Acids Res. 1989, 17, 7195-7200.
16. McGuigan, C.; Colin, B.; Jones, B.C.N.; Riley, P.A. Trans-esterification reactions yield novel masked phosphate derivatives of the anti-cancer agent araC. Bioorg. Med. Chem. Lett. 1991, 1, 607-610.
17. McGuigan, C.; Jones, B.C.N.; Tollerfield, S.M.; Riley, P.A. Synthesis and biological evaluation of haloalkyl phosphate triester derivatives of AraA and AraC. Antiviral Chem. Chemother. 1992, 3, 79-94.
18. Abraham, T.W.; Kalman, T.I.; McIntee, E.J.; Wagner, C.R. Synthesis and biological activity of aromatic amino acid phosphoramidates of 5′-fluoro-2′-deoxyuridine and 1-beta-arabinofuranosylcytosine: Evidence of phosphoramidase activity. J. Med. Chem. 1996, 39, 4569-4575.
19. Tobias, S. C.; Borch, R.F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharmaceutics 2004, 1, 112-116.
20. Périgaud, C.; Gosselin, G.; Imbach, J.-L. Anti-HIV phosphotriester nucleotides. Basis for the rational design of biolabile phosphate protection. In Biomedical Chemistry/Applying Chemical Principles to the Understanding and Treatment of Disease; John Wiley & Sons Inc.: New York, 2000; 115-141.
21. Peyrottes, S.; Egron, D.; Lefebvre, I.; Gosselin, G.; Imbach, J.L.; et al. SATE pronucleotide approaches: An overview. Mini-Rev. Med. Chem. 2004, 4, 395-408.
22. Périgaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J.-L.; Benzaria, S.; et al. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 1993, 3, 2521-2526.
23. Périgaud, C.; Girardet, J.-L.; Gosselin, G.; Imbach, J.-L. Comments on nucleotide delivery forms. In Antiviral Drug Design; JAI Press: London, 1996; 147-172.
24. Périgaud, C.; Gosselin, G.; Imbach, J.-L. Minireview: From the pronucleotide concept to the SATE phosphate protecting groups. In Current Topics in Medicinal Chemistry; Blackwell Science Ltd.: Oxford, 1997; 15-29.
25. Bazzanini, R.; Manfredini, S.; Durini, E.; Gröschel, B.; Cinatl, J.; et al. Prodrugs of Ara-CMP and Ara-AMP with S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: Synthesis and biological evaluation. Nucleosides Nucleotides 1999, 18, 971-972.
26. Gröschel, B.; Cinatl, J.; Kotchetkov, R.; Kohl, U.; Rohrbach, E.; et al. Cytotoxic activity and pharmacology of an ara-CMP prodrug in T-leukemic sublines resistant to Ara-C. In Hematology and Blood Transfusion 39. Acute Leukemias VII. Experimental Approaches and Novel Therapies; Springer-Verlag Berlin: Heidelberg, 1998; 628-632.
27. Lannuzel, M.; Egron, D.; Imbach, J.L.; Gosselin, G.; Perigaud, C. Synthesis of the tBuSATE pronucleotide of AZT by two different synthetic approaches. Nucleosides Nucleotides 1999, 18, 1001-1002.
28. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; et al. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate protecting groups. Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
29. Menger, F.M.; Guo, Y.; Lee, A.S. Synthesis of a lipid/peptide/drug conjugate: N4-(acylpeptidyl)-Ara-C. Bioconj. Chem. 1994, 5, 162-166.
30. Wipf, P.; Li, W.; Sekhar, V. Synthesis of chemoreversible prodrugs of Ara-C. Bioorg. Med. Chem. Lett. 1991. 1, 745-750.
31. Gray, S.H.; Ainsworth, C.F.; Bell, C.L.; Danyluk, S.S.; McCoss, M. Synthesis of deoxyribonucleotidyl-(3′-5′)arabinonucleosides. Nucleosides Nucleotides 1983, 2, 435-452.
32. Perich, J.W.; Johns, R.B. Di-tert-butyl N,N-diethylphosphoramidite. A new phosphatylating agent for efficient phosphorylation of alcohol. Synthesis 1988, 142-144.
33. Zhang, W.; Robins, M.J. Removal of silyl protecting groups from hydroxyl functions with ammonium fluoride in methanol. Tetrahedron Lett. 1992, 33, 1177-1180.
34. Kremsky, J.N.; Sinha, N.D. Facile deprotection of silyl nuclesides with potassium fluoride/18-crown-6. Bioorg. Med. Chem. Lett. 1994, 4, 2171-2174.
35. Ogilvie, K.K.; Schifman, A.L.; Penney, C.L. The synthesis of oligoribonucleotides. III. The use of silyl protecting groups in nucleoside and nucleotide chemistry. VIII. Can. J. Chem. 1979, 57, 2230-2238.
36. Baker, D.C.; Haskell, T.H.; Putt, S.R.; Sloan, B.J. Prodrugs of 9-(b-D-arabinofuranosyl)adenine 2. Synthesis and evaluation of a number of 2′,3′- and 3′,5′-di-O-acyl derivatives. J. Med. Chem. 1979, 22, 273-279.
37. Baker, D.C.; Kumar, S.D.; Waites, W.J.; Arnett, G.; Shannon, W.M.; et al. Synthesis and evaluation of a series of 2′-O-acyl derivatives of 9-β-D-arabinofuranosyladenine as antiherpes agents. J. Med. Chem. 1984, 27, 270-274.
38. Basel, Y.; Hassner, A. Di-tert-butyl dicarbonate and 4-(dimethylamino) pyridine revisited. Their reactions with amines and alcohols. J. Org. Chem. 2000, 65, 6368-6380.
39. Corey, E.J.; Venkateswarlu, A. Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives. J. Am. Chem. Soc. 1972, 94, 6190-6191.
40. Bunch, L.; Norrby, P.-O.; Frydenvang, K.; Krogsgaard-Larsen, P.; Madsen, U. Unprecedented migration of N-alkoxycarbonyl groups in protected pyroglutaminol. Org. Lett. 2001, 3, 433-435.
41. Anzai, K.; Uzawa, J. Acyl mgration on nucleic acid compounds related to adenosine. Nucl. Acids Symp. Series 1985, 16, 101-103.
42. Anderson, B.D.; Fung, M.C.; Kumar, S.D.; Baker, D.C. Hydrolysis and solvent dependent 2′,5′ and 3′,5′ acyl migration in prodrugs of 9-beta-D-arabinofuranosyladenine. J. Pharm. Sci 1985, 74, 825-830.
43. Pirrung, M.C.; Shuey, S.W.; Lever, D.C.; Fallon, L. A convenient procedure for the deprotection of silylated nucleosides and nucleotides using triethylamine trihydrofluoride. Bioorg. Med. Chem. Lett. 1994, 4, 1345-1346.
44. Westman, E.; Stromberg, R. Removal of t-butyldimethilsilyl protection in RNA-synthesis. Triethylamine trihydrofluoride (TEA•3HF) is a more reliable alternative to tetrabutylammonium fluoride (TBAF). Nucl. Acids Res. 1994, 22, 2430-2431.
45. Gasparutto, D.; Livache, T.; Bazin, H.; Duplaa, A.M.; Guy, A.; et al. Chemical synthesis of a biologically active natural tRNA with its minor bases. Nucl. Acids Res. 1992, 20, 5159-5166.
46. Ogilvie, K.K.; McGee, D.P.C.; Boisvert, S.M.; Hakimelahi, G.; Proba, Z.A. The preparation of protected arabinonucleosides. Can. J. Chem. 1983, 61, 1204-1212.